How to Cite
Abstract
In this study we established a HER2/neu expressing mouse tumor model using hepatoma MH-22a cell line tumorigenic in DBA mice. G10 clone with high level of HER2/neu expression was obtained by stable transfection and cloning. Solid tumors induced by subcutaneous injection of G10 cells into immunocompetent mice retain the expression of human receptor for at least three weeks. Treatment with trastuzumab results in statistically significant inhibition of tumor growth. This model can be used to evaluate in vivo efficiency of novel anti-HER2/neu antibodies and to test antibody-based conjugates for diagnostics.References
Mendelsohn J. Blockade of receptors for growth factors: an anti-cancer therapy. // Clinical Cancer Research - 2000. - Vol. 6. - P. 747-753.
Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. // Endocr. Relat. Cancer - 2001. - Vol. 8 (1). - P. 3-9.
Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. // Current Opinion in Immunology - 2004. - Vol. 16. - P 143-150.
Ponder B.A., Wilkinson M.M. Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. // J. Histochem. Cytochem - 1981. - Vol. 29. - P 981-984.
Slamon, D.J., Clark G.M, Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. // Science - 1987. -Vol. 235 (4785). - P. 177-182.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...